A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission. Methods We studied patients with a new diagnosis of generalized vasculitis and a serum creatinine concentration of 5.7 mg per deciliter (500 micromol per liter) or less. All patients received at least three months of therapy with oral cyclophosphamide and prednisolone. After remission, patients were randomly assigned to continued cyclophosphamide therapy (1.5 mg per kilogram of body weight per day) or a substitute regimen of azathioprine (2 mg per kilogram per day). Both groups continued to receive prednisolone and were followed for 18 months from study entry. Relapse was the primary end point. Results Of 155 patients studied, 144 (93 percent) entered remission and were randomly assigned to azathioprine (71 patients) or continued cyclophosphamide (73 patients). There were eight deaths (5 percent), seven of them during the first three months. Eleven relapses occurred in the azathioprine group (15.5 percent), and 10 occurred in the cyclophosphamide group (13.7 percent, P=0.65). Severe adverse events occurred in 15 patients during the induction phase (10 percent), in 8 patients in the azathioprine group during the remission phase (11 percent), and…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment includes prednisone, cyclophosphamide, or methotrexate.237,238,245”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [245]
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Self-citationWegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
FAUCI, A. S., HAYNES, B. F., KATZ, P., & WOLFF, S. M. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-1-76 · Cited by 2,001
Short form 36 (SF36) health survey questionnaire: normative data for adults of working age.
Jenkinson, C., Coulter, A., & Wright, L. (1993) · BMJ · doi:10.1136/bmj.306.6890.1437 · Cited by 1,718
Falk, R. J., Terrell, R. S., Charles, L. A., & Jennette, J. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4115 · Cited by 1,261
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056
Self-citationSavige, J., Gillis, D., Benson, E., Davies, D., Esnault, V., Falk, R. J., Chris Hagen, E., Jayne, D., Charles Jennette, J., Paspaliaris, B., et al. (1999) · American Journal of Clinical Pathology · doi:10.1093/ajcp/111.4.507 · Cited by 884
Self-citationValidation of rheumatoid arthritis improvement criteria that include simplified joint counts
van Gestel, A. M., Haagsma, C. J., & van Riel, P. L. C. M. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k · Cited by 803
Research works printed but not linked: 10
- Jennette JC, 1989, Am J Pathol, 135, 921
- Hauer HA, 1998, Clin Exp Immunol, 112, 28
- 10.1002/(SICI)1096-9896(200002)190:3<349::AID-PATH524>3.0.CO;2-A · doi:10.1002/(sici)1096-9896(200002)190:3<349::aid-path524>3.0.co;2-a
- 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J · DOI · Paper page
- Jayne DR, 1995, QJM, 88, 127
- Luqmani RA, 1994, QJM, 87, 671
- Bacon PA, 1995, Clin Exp Rheumatol, 13, 275
- 10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q · doi:10.1002/1529-0131(199810)41:10<1835::aid-art16>3.0.co;2-q
- Szpirt WM, 1996, Int J Artif Organs, 19, 501
- 10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F · DOI · Paper page
Cited by
Items 901–999 of 999
Progress in peripheral nerve disease research in the last two years
Evans, M. R. B., & Manji, H. (2013) · Journal of Neurology · doi:10.1007/s00415-013-7121-x · Cited by 3
“Given the cumulative dose-related toxicity of cyclophosphamide, once remission is achieved a maintenance drug—usually azathioprine [16], is added.”
BackgroundPulmonary renal syndromes: A pulmonologist's view
Nath, A., & Rajagopala, S. (2015) · Clinical Queries Nephrology · doi:10.1016/j.cqn.2015.02.001 · Cited by 3
Miyawaki, K., Shiraishi, J., Tsutsumi, Y., Shiraishi, E., Ohtsuki, K., Inoue, M., Tatsumi, T., Azuma, A., & Matsubara, H. (2006) · Angiology · doi:10.1177/0003319706290736 · Cited by 3
Hoffman, G. S., & Langford, C. A. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0100 · Cited by 3
A Case of Treated ANCA-Associated Vasculitis with Recurrent Renal Failure
Salama, A. D., Cook, H. T., Pusey, C. D., & Pepper, R. J. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05071107 · Cited by 3
“In the Cycazarem trial, 18% of patients with WG and 8% of those with MPA relapsed within 18 mo (6).”
BackgroundSelf-citationFoster, R., & D’Cruz, D. P. (2007) · Expert Review of Obstetrics & Gynecology · doi:10.1586/17474108.2.5.681 · Cited by 3
Outcome measures for antineutrophil cytoplasmic antibody-associated vasculitis
Tómasson, G. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000135 · Cited by 3
“However, remission in AAV is associated with substantially reduced HRQoL [9,21,43], unlike in the case of RA, where the remission state is associated with almost achieving population norms in terms of HRQoL [44].”
BackgroundMethodInfluentialPeixoto, L., Aguiar, P., Veloso, F., Espirito, J., Marques, N. S., de Jesus, I., & Nogueir, J. M. B. (2011) · InTech eBooks · doi:10.5772/20014 · Cited by 4
“According to the CYCAZAREM trial (40), the former is safer than and as effective as cyclophosphamide.”
BackgroundGlomerulonephritis and Interstitial Nephritis
Kahl, C. R., & Falk, R. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1367-1.00118-x · Cited by 4
Therapiedeeskalation bei ANCA-assoziierten Vaskulitiden
Schinke, S., Riemekasten, G., & Lamprecht, P. (2016) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-016-0241-9 · Cited by 3
Nierenbeteiligung bei ANCA-assoziierten Vaskulitiden
Haubitz, M. (2018) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-106566 · Cited by 3
“In einer EUVAS-Studie (CYCAZAREM) bei Patienten mit einer generalisierten AAV ohne lebensbedrohliche Manifestation und ohne Nierenversagen (Kreatinin < 500 μmol) wurden Patienten nach dem Erreichen einer Remission randomisiert und entweder mit CP weiterbehandelt (1,5mg/kg KG oral, insgesamt 1 Jahr) oder auf eine Thera…”
BackgroundThe 2010 Nephrology Quiz and Questionnaire: Part 2
Glassock, R. J., Bleyer, A. J., Bargman, J. M., & Fervenza, F. C. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06500711 · Cited by 3
Intapiboon, P., & Siripaitoon, B. (2020) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001456 · Cited by 3
Glomérulonéphrites extracapillaires
Esnault, V. L. M., Moreau, A., Testa, A., & Besnier, D. (2006) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2006.06.007 · Cited by 3
Management and Outcomes of ANCA-Associated Vasculitis at a Tertiary Healthcare Facility
Moollan, N., Ahmed, A. R., & Denton, M. (2022) · Autoimmune Diseases · doi:10.1155/2022/4808806 · Cited by 3
“Azathioprine was the choice of maintenance therapy which is standard practice as it has shown to be equivalent to cyclophosphamide and superior to mycophenolate mofetil (MMF) in remission maintenance [16, 17].”
BackgroundStone, J. H. (2008) · Springer eBooks · doi:10.1007/978-0-387-68566-3_53 · Cited by 3
Karia, V. R., & Espinoza, L. R. (2009) · Current Rheumatology Reports · doi:10.1007/s11926-009-0061-x · Cited by 3
“Current randomized, controlled trials show higher relapse rates in trials that discontinued corticosteroids in the fi rst 6 months [21] or 12 months [22] compared with those who continued to administer prednisolone for 18 months and longer [ 23 ].”
BackgroundAsbestos and Probable Microscopic Polyangiitis
Philteos, G., Coverett, K., Chibbar, R., Ward, H. A., & Cockcroft, D. W. (2004) · Canadian Respiratory Journal · doi:10.1155/2004/341942 · Cited by 3
“However, the clinical and serological picture suggested a systemic vasculitis, probably microscopic polyangiitis (5).”
BackgroundIudici, M., Puéchal, X., Brigante, A. J., Atal, I., & Gabay, C. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01408-6 · Cited by 3
Rituximab and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Wong, C. F. (2008) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31816b449e · Cited by 3
“Despite cyclophosphamide and steroids being the mainstay of treatment for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), up to 10% of cases remain refractory.(1) For these refractory patients and those intolerant of the conventional therapy, recent successful reports of response with rituximab…”
BackgroundEditorial, A. (2024) · Nephrology and Dialysis · doi:10.28996/2618-9801-2024-4-397-434 · Cited by 3
Aguirre, V., Alvo, M., Ardiles, L. G., Fierro, A., Annelise Goecke, S., Iruretagoyena, M., Jalil, R., Massardo, L., Méndez, G. P., Palma, S. L. L., et al. (2018) · Revista médica de Chile · doi:10.4067/s0034-98872018000200241 · Cited by 3
Ni, A., Xu, Y., Chen, J., & Han, F. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s494848 · Cited by 5
Update on antineutrophil cytoplasmic antibody vasculitis
Mandel, D. A., Shekhar, N., Hanna, R. M., & Reddy, U. G. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001146 · Cited by 2
Vasculitis 2013. What are the changes introduced in the 2012 Chapel Hill Consensus Conference?
Zeher, M. (2013) · Orvosi Hetilap · doi:10.1556/oh.2013.29704 · Cited by 2
Microscopic polyangiitis in a patient on hemodialysis : A case report.
Horai, Y., Miyamura, T., Takahama, S., Sonomoto, K., Nakamura, M., Ando, H., Minami, R., Yamamoto, M., & Suematsu, E. (2009) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.32.506 · Cited by 2
Akutes Nierenversagen und Vaskulitis: Wann dran denken und was tun ?
Wilde, B., Bienholz, A., Witzke, O., & Kribben, A. (2015) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0041-100519 · Cited by 2
Erdbrügger, U., Kielstein, J. T., Westman, K. W. A., Ma, J. Z., Xin, W., Bode-Böger, S. M., Segelmark, M., Rasmussen, N., & de Groot, K. (2018) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2018.17119 · Cited by 2
Self-citationAdult and Childhood Vasculitis of the Nervous System
Younger, D. S. (2019) · Current clinical neurology · doi:10.1007/978-3-030-24436-1_14 · Cited by 2
Multiple pulmonary nodules in granulomatous polyangiitis: A case series
Arunsurat, I., Reechaipichitkul, W., So-ngern, A., Chaisuriya, N., Mahankkanukrauh, A., Ratanawatkul, P., Chumpangern, W., & Kampan, P. (2020) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2020.101043 · Cited by 2
Update on Maintenance Therapies for ANCA-Associated Vasculitis
Pagnoux, C., & Fifi-Mah, A. V. (2021) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-021-00176-z · Cited by 2
Antineutrophilic cytoplasmic antibody-associated vasculitis and the kidney
Balani, S. S., Kizilbash, S. J., & Kouri, A. M. (2021) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001102 · Cited by 2
Contreras, K., Orozco, V., Puche, E. J., González, C. A., García, P., Rodríguez, M. P., & Rosselli, D. (2021) · Value in Health Regional Issues · doi:10.1016/j.vhri.2021.08.002 · Cited by 2
Vasculitis: What Have We Learned in the Last 50 Years?
Carette, S. (2022) · The Journal of Rheumatology · doi:10.3899/jrheum.220207 · Cited by 3
Treatment strategies for ANCA-associated vasculitides: from standard protocols to future horizons
Reggiani, F., Stella, M., Calatroni, M., & Sinico, R. A. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2326628 · Cited by 3
“…study [69]. a IV methylprednisolone 500–1,000 mg/day for 3–5 days (total cumulative dose 1–3 g) should be considered in patients with severely active disease. maintenance therapy following both induction with RTX or CYC [53], while AZA, MMF and MTX are considered as possible alternatives [102–104].”
Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden
Holle, J. U., Kubacki, T., Aries, P., Hellmich, B., Kernder, A. L., Kneitz, C., Lamprecht, P., Schirmer, J. H., Schreiber, A., Berlit, P., et al. (2025) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-024-01596-7 · Cited by 2
Long-term risk of malignancies in ANCA-associated vasculitis
Álamo, B. S., Chiappe, S. G., Moi, L., Bajema, I. M., Faurschou, M., Floßmann, O., Heijl, C., Jayne, D. R. W., Mahr, A., & Westman, K. W. A. (2025) · EULAR Rheumatology Open · doi:10.1016/j.ero.2025.08.007 · Cited by 2
Self-citationGranulomatosis with Polyangiitis (Wegener’s Granulomatosis)
Pagnoux, C., & Villa‐Forte, A. (2014) · Springer eBooks · doi:10.1007/978-1-4471-2401-6_9 · Cited by 2
Schreiber, A., Göbel, U., & Kettritz, R. (2009) · Der Nephrologe · doi:10.1007/s11560-009-0311-y · Cited by 2
Shibata, T., Mizushima, M., Shibata, T. N., Yamasaki, Y., Nagafuchi, H., Yamada, H., & Ozaki, S. (2015) · Journal of St Marianna University · doi:10.17264/stmarieng.6.23 · Cited by 2
Necrotizing Arteritis and Small Vessel Vasculitis
Jennette, J. C., & Falk, R. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-384929-8.00072-1 · Cited by 2
Lamprecht, P., & Gross, W. L. (2001) · Springer eBooks · doi:10.1007/978-3-7091-3704-8_12 · Cited by 2
Self-citationBalancing efficacy and cancer risk of cyclophosphamide for patients with Wegener's granulomatosis
Molloy, E. S., & Langford, C. A. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0822 · Cited by 2
L51. From immunosuppression to selective treatments: The benefit–risk ratio
Guillevin, L. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.01.046 · Cited by 2
L50. The future of international clinical trials in vasculitis
Merkel, P. A. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.02.001 · Cited by 2
Treatment of primary systemic necrotizing vasculitides: the role of biotherapies
Guillevin, L. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0860-2 · Cited by 2
“The results of several studies demonstrated that short-term cyclophosphamide administration until remission, followed by azathioprine, was as effective as prolonged oral cyclophosphamide [20].”
BackgroundSystemische ANCA-assoziierte Vaskulitis – Diagnostik und Therapie
Eisenberger, U., & Hess, C. (2008) · Therapeutische Umschau · doi:10.1024/0040-5930.65.5.295 · Cited by 2
“nach etwa 3–6 Monaten) auf das weniger toxische Azathioprin oral möglich ist, ohne an Therapieeffektivität einzubüßen [11].”
BackgroundGlomerulopatías secundarias a enfermedades sistémicas
Rojas-Rivera, J. E., Barat, A., & Egido, J. (2011) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(11)70138-x · Cited by 2
Manifestations rénales des maladies auto-immunes systémiques : diagnostic et traitement
O’Callaghan, C. A. (2006) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2006.04.001 · Cited by 2
Clinical immunology – Autoimmunity in the Netherlands
Tervaert, J. W. C., & Kallenberg, C. G. M. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.10.008 · Cited by 2
Self-citationRole and place of methotrexate in vasculitis management
Pagnoux, C., & Goulet, M. (2009) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.09.52 · Cited by 2
Rašić, S., Džemidžić, J., Karasalihović, Z., Herenda, V., & Rebić, D. (2012) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2012.2535 · Cited by 2
Update on the Classification Criteria for Vasculitis
Kim, H. W., & Hur, J.-W. (2014) · Korean Journal of Medicine · doi:10.3904/kjm.2014.87.4.401 · Cited by 2
“Wegener’s Granulomatosis Etanercept trial (WGET) 시험에서는 재발률을 57%로 높게 보고한 반면, CYCAZAREM 그룹은 15% 정도의 상대적으로 낮은 재발률을 보고하였다[34,35].”
Rituximab as Maintenance Therapy for ANCA Associated Vasculitis: How, When and Why?
Alba, M. A., & Flores-Suárez, L. F. (2015) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2015.06.001 · Cited by 2
Approach to the Patient with Chronic Glomerular Disease
Cohen, S. D., & Appel, G. B. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00037-8 · Cited by 2
Stratégies d’immunothérapie ciblée au cours des vascularites associées aux ANCA
Puéchal, X. (2018) · Revue du Rhumatisme · doi:10.1016/j.rhum.2018.06.005 · Cited by 2
Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Sattui, S. E., & Spiera, R. (2019) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2019.04.006 · Cited by 3
Brown, K. M., Frankel, S. K., & Cool, C. D. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00060-9 · Cited by 2
Antineutrophil Cytoplasm Antibody–Associated Vasculitis
Savage, C. O. S., & Harper, L. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00089-x · Cited by 2
Treatment and Management of Autoimmune Neuropathies
El-Abassi, R. N., Soliman, M. Y., Levy, M. H., & England, J. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-71317-7.00015-9 · Cited by 2
Proteinase 3 associated with Wegener's granulomatosis
Goldmann, W. H. (2021) · Cell Biology International · doi:10.1002/cbin.11757 · Cited by 2
Petrou, D., Karagiannis, M., Nikolopoulos, P. M., Liapis, G., & Lionaki, S. (2022) · Antibodies · doi:10.3390/antib11020033 · Cited by 2
Panarteriitis nodosa und verwandte Zustände (M 30)
Mayet, W.-J. (2008) · Springer eBooks · doi:10.1007/978-3-540-34105-5_56 · Cited by 2
Guilpain, P., & Guillevin, L. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-285-8_19 · Cited by 2
Haubitz, M. (2015) · Der Nephrologe · doi:10.1007/s11560-015-0024-3 · Cited by 2
Lelong, J., Tillie‐Leblond, I., & Tonnel, A. (2006) · Encyclopédie médico-chirurgicale. Pneumologie · doi:10.1016/s1155-195x(06)35993-2 · Cited by 2
Itabashi, M., Takei, T., Moriyama, T., Shiohira, S., Shimizu, A., Tsuruta, Y., Uchida, K., & Nitta, K. (2013) · Modern Rheumatology · doi:10.1007/s10165-012-0829-0 · Cited by 2
Small and medium vessel primary vasculitis
Stone, J. H. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7234-3691-1.00071-4 · Cited by 2
Johnsen, A. K., & Weinblatt, M. E. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00053-1 · Cited by 2
Steroid Sparing Therapies for Antineutrophil Cytoplasmic Autoantibodies Associated Vasculitis
Ramirez, M. J. Z., Vu, D., & Jain, K. (2022) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2022.08.002 · Cited by 2
Granulomatosis with polyangiitis and microscopic polyangiitis: common features and differences
Litvinova, M. A., Bulanov, N., Novikov, P., Vlasenko, N. O., Filatova, E., Kurginyan, K., Вячеславович, С. А., & Moiseev, S. (2023) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2023-1-64-72 · Cited by 2
Wang, H. Y., Robson, D. C., & Kim, S. J. (2023) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2023.07.002 · Cited by 2
Chapter 44 Vasculitis and stroke
Scolding, N. J. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(08)93044-x · Cited by 2
Cyclophosphamid oral vs. Bolus bei Wegener-Granulomatose und anderen ANCA-assoziierten Vaskulitiden
Reinhold‐Keller, E., & Warnatz, K. (2008) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-008-0415-1 · Cited by 2
A man with Wegener's granulomatosis and haemoptysis
Lee, R., Martin, R., & D’Cruz, D. P. (2009) · BMJ · doi:10.1136/bmj.b1461 · Cited by 2
What does pulmonary–renal syndrome stand for?
Farag, T. S., & Farag, A. S. (2018) · Egyptian Journal of Bronchology · doi:10.4103/ejb.ejb_6_17 · Cited by 2
Garner, S., & KHALIDI, N. A. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104038 · Cited by 2
Harper, L., & Weidanz, F. (2006) · Medicine · doi:10.1053/j.mpmed.2006.08.005 · Cited by 2
SYSTEMIC DISORDERS THAT ALSO INVOLVE THE CEREBROVASCULAR SYSTEM
Caplan, L. R., & Bogousslavsky, J. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544897.044 · Cited by 2
MANAGEMENT OF REFRACTORY SYSTEMIC RHEUMATIC DISEASES
Houssiau, F. (2003) · Acta Clinica Belgica · doi:10.1179/acb.2003.58.5.009 · Cited by 2
“This approach was recently supported by prospective studies performed in ANCA-associated vasculitis (1) and lupus nephritis (2).”
ResultBacon, P. A., & Wollheim, F. A. (2011) · Lara D. Veeken · doi:10.1093/rheumatology/ker369 · Cited by 2
Self-citationFloßmann, O., & de Groot, K. (2007) · Nature Reviews Nephrology · doi:10.1038/ncpneph0468 · Cited by 2
Husten, Rhinitis, Fieber, hämorrhagischer Schock
Renzulli, P., Winiger, I., Weimann, R., Berg, P., Gugger, M., & Candinas, D. (2008) · Der Pneumologe · doi:10.1007/s10405-008-0251-7 · Cited by 2
Intravenous methylprednisolone or plasma exchange for adjunctive therapy of severe renal vasculitis?
Salant, D. J. (2007) · Nature Reviews Nephrology · doi:10.1038/ncpneph0650 · Cited by 2
Roadmap to vasculitis: a rheumatological treasure hunt
Konttinen, Y., Pettersson, T., Matucci‐Cerinic, M., Dadonienė, J., & Poduval, P. (2007) · Indian Journal of Rheumatology · doi:10.1016/s0973-3698(10)60022-2 · Cited by 2
Self-citationNeue Therapiekonzepte bei Vaskulitiden und Kollagenosen
Metzler, C., Hellmich, B., & Gause, A. (2005) · Der Internist · doi:10.1007/s00108-005-1516-4 · Cited by 2
Scolding, N. J., Wilson, H., Hohlfeld, R., Polman, C. H., Leite, M. I., & Gilhus, N. E. (2010) · doi:10.1002/9781444328394.ch35 · Cited by 2
Levell, N. J., & Mukhtyar, C. B. (2016) · doi:10.1002/9781118441213.rtd0103 · Cited by 2
Stein, C. M., & Taylor, H. G. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3285-4.10057-9 · Cited by 2
ANCA-associated systemic vasculitis (AASV)
Kluth, D., & Hughes, J. (2007) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/1478271520073702015 · Cited by 2
A case of granulomatosis with polyangiitis preceded by subacute thyroiditis
Mukae, H., Furusyo, N., Murata, M., Ogawa, E., Kainuma, M., Shimizu, M., Ihara, T., & Hayashi, J. (2014) · Clinical Case Reports · doi:10.1002/ccr3.181 · Cited by 1
“However, this treatment is difficult because it can cause serious side effects [16].”
BackgroundIwasawa, A., Ikegaya, N., Saitou, M., Kaname, S., Arimura, Y., Yamada, A., & Ogawa, M. (2009) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.42.777 · Cited by 1
CADTH (2023) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2023.762 · Cited by 1
The Expanding Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Armamentarium
McGovern, D., Jones, R. B., Jayne, D. R. W., & Smith, R. (2025) · Drugs · doi:10.1007/s40265-024-02143-z · Cited by 1
“Clinical trials have allowed for clinicians to reduce cumulative cyclophosphamide exposure by replacing daily oral dosing for induction with pulsed intravenous dosing and subsequent maintenance with azathioprine [62, 63].”
Self-citationBulanov, N. M., Zakharova, E., Kozlovskaya, N. L., Vatazin, A., Karunnaya, A. V., & Dobronravov, V. (2025) · Nephrology and Dialysis · doi:10.28996/2618-9801-2025-2-116-166 · Cited by 1
Neary, E., Healey, K., Clements‐Baker, M., Makhzoum, J., & Mendel, A. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152900 · Cited by 2
Recent pathogenetic insights and therapeutic advances in ANCA-associated vasculitis.
Sagy, I., & Jayne, D. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.11.024 · Cited by 1
Self-citationChatzikyrkou, C., Herzog, C., Ganz, M. J., Wiech, T., Gröne, H., Mertens, P. R., & Scurt, F. G. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag079 · Cited by 1
“All patients r ecei v ed standard car e according to esta b lished pr o-tocols [ 21–24 ].”
Pozzolo, R. D., Iorio, L., Davanzo, F., Zanatta, E., Iaccarino, L., Ramonda, R., Gerli, R., Doria, A., Cafaro, G., & Padoan, R. (2026) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-026-09147-5 · Cited by 3
Metadata
- Authors
- Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., Gross, W., Hagen, E. C., Mirapeix, E., Pettersson, E., Siegert, C., Sinico, A., Tesar, V., Westman, K., & Pusey, C.
- Affiliations
- Addenbrooke's Hospital (GB)
- Rigshospitalet (DK)
- University of Birmingham (GB)
- Maastricht University (NL)
- University of Helsinki (FI)
- Imperial College London (GB)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Lübeck (DE)
- Hospital Clínic de Barcelona (ES)
- Leiden University Medical Center (NL)
- Azienda Ospedaliera Ospedale San Carlo Borromeo (IT)
- Lund University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-03
- Volume
- 349
- Issue
- 1
- Pages
- 36-44
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1981535363
- Cited by
- 1,348
- References
- 44
- Citations by year
- 2026: 6 · 2025: 22 · 2024: 24 · 2023: 37 · 2022: 48 · 2021: 36 · 2020: 51 · 2019: 46 · 2018: 51 · 2017: 46 · 2016: 51 · 2015: 80 · 2014: 77 · 2013: 80 · 2012: 83
- FWCI
- 48.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Keywords
- ANCA-associated vasculitis, maintenance therapy, cyclophosphamide, azathioprine, granulomatosis with polyangiitis, microscopic polyangiitis, relapse, remission, prednisolone, adverse events
- MeSH terms
- Adult, Aged, Azathioprine, Cyclophosphamide, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunosuppressive Agents, Male, Middle Aged, Neutropenia, Prednisolone, Recurrence, Remission Induction, Vasculitis, Antibodies, Antineutrophil Cytoplasmic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.